NasdaqCM:SLNOBiotechs
Soleno Lawsuit Puts DCCR Safety Disclosures And Growth Story Under Scrutiny
A class action lawsuit has been filed against Soleno Therapeutics (NasdaqCM:SLNO) alleging failures to disclose significant safety concerns in clinical trials for its drug DCCR.
The complaint targets the company and certain executives, claiming that undisclosed issues could affect DCCR's commercial prospects and Soleno's reputation.
The case focuses on the period around the development and launch preparations of DCCR, Soleno's sole commercial product.
Soleno Therapeutics is a biotech...